BioPharma Dive4h
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...
BioPharma Dive7h
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...
BioPharma Dive5h
Lilly’s Omvoh approved by FDA for Crohn’s
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...
BioPharma Dive4h
‘The bar has risen’: China’s biotech gains push US companies to adapt
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive at the J.P. Morgan Healthcare ...